Tyme Provides Clinical and Corporate Update for Fiscal Third Quarter 2017
February 07, 2018 09:44 ET
|
Tyme Technologies, Inc.
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced a clinical and corporate...
Tyme Announces Prostate Cancer Collaboration with Dr. Mack Roach III of UCSF
January 30, 2018 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that Mack Roach III, M.D.,...
Tyme Announces Positive Efficacy Data for SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers Symposium
January 19, 2018 11:46 ET
|
Tyme Technologies, Inc.
40 percent of evaluable patients achieved survival of more than 12 months, 30 percent achieved a complete or partial tumor responseAll patients improved or maintained quality of life measures and pain...
Tyme Announces Presentation of Clinical Data on SM-88 in Prostate Cancer at 2018 ASCO Genitourinary Cancers Symposium
January 04, 2018 08:00 ET
|
Tyme Technologies, Inc.
Mack Roach, M.D., FASCO, University of California, San Francisco, to present data from ongoing Phase II clinical trial NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc....
Tyme to Present at 36th Annual J.P. Morgan Healthcare Conference
January 03, 2018 07:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that management will present...
Tyme to Present Efficacy Data on SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers Symposium
December 19, 2017 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that efficacy data from its...
Tyme to Present at Biotech Showcase™ 2018
December 13, 2017 12:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that management will present a company...
Tyme Provides Update on At-The-Market Financing Activity
December 05, 2017 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, announced it has raised gross proceeds of...
Tyme to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
November 13, 2017 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced that...
Tyme Provides Clinical and Corporate Update for the Fiscal First Half 2017
November 08, 2017 07:30 ET
|
Tyme Technologies, Inc.
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced an update of its clinical...